Alnylam Pharma (DUL) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DUL Analyst Ratings

Strong Buy

19 Buy

3 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Alnylam

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DUL Stock 12 Month Forecast

Average Price Target

€328.62

▲(31.82% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is €328.62 with a high forecast of €479.02 and a low forecast of €222.96. The average price target represents a 31.82% change from the last price of €249.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"176":"€176","252":"€252","328":"€328","404":"€404","480":"€480"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":479.0223075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€479.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":328.6180124415,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€328.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":222.9631104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€222.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[176,252,328,404,480],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,206.9,227.8324851923077,248.7649703846154,269.69745557692306,290.62994076923076,311.56242596153845,332.49491115384615,353.42739634615384,374.35988153846154,395.29236673076923,416.2248519230769,437.1573371153846,458.0898223076923,{"y":479.0223075,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,206.9,216.26292403396155,225.62584806792307,234.98877210188462,244.35169613584617,253.7146201698077,263.0775442037692,272.4404682377308,281.8033922716923,291.1663163056538,300.5292403396154,309.8921643735769,319.25508840753844,{"y":328.6180124415,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,206.9,208.1356238769231,209.37124775384615,210.60687163076923,211.84249550769232,213.07811938461538,214.31374326153846,215.54936713846155,216.78499101538463,218.0206148923077,219.25623876923078,220.49186264615386,221.72748652307692,{"y":222.9631104,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":377.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":393.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":392.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":288.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":206.9,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€479.02

Average Price Target€328.62

Lowest Price Target€222.96

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

09/18/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Dexcom (NASDAQ: DXCM) and Alnylam Pharma (NASDAQ: ALNY)

Joseph Stringer

Needham

€310.93

Buy

24.72%

Upside

Reiterated

09/17/26

Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity

David Lebowitz

BMO Capital

€276.96

Buy

11.10%

Upside

Reiterated

09/17/26

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and Alnylam Pharma (NASDAQ: ALNY)

Jeffrey Walch

Bernstein

€327.48

Buy

31.36%

Upside

Reiterated

09/16/26

Analysts' Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)

Michael Ulz

Morgan Stanley

€261.28

Hold

4.81%

Upside

Reiterated

09/11/26

Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained

Faisal Khurshid

Jefferies

€200.32→€226.45

Hold

-9.17%

Downside

Reiterated

09/08/26

Alnylam price target raised to $260 from $230 at JefferiesAlnylam price target raised to $260 from $230 at Jefferies

Patrick Trucchio

H.C. Wainwright

€396.28

Buy

58.96%

Upside

Reiterated

09/02/26

Alnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target

Eliana Merle

Barclays

€391.93

Buy

57.21%

Upside

Reiterated

09/01/26

Barclays Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Cory Kasimov

Evercore ISI

€283.23

Buy

13.61%

Upside

Reiterated

08/31/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Matteis

Stifel Nicolaus

€276.96

Buy

11.10%

Upside

Reiterated

08/31/26

Stifel Nicolaus Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Eric Joseph

Citi

€296.12

Buy

18.78%

Upside

Reiterated

08/31/26

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY)

Tazeen Ahmad

Bank of America Securities

€301.35

Buy

20.88%

Upside

Reiterated

08/31/26

Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility

Edward Tenthoff

Piper Sandler

€425.89

Buy

70.84%

Upside

Reiterated

08/31/26

Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Whitney Ijem

Canaccord Genuity

€373.64

Buy

49.87%

Upside

Reiterated

08/28/26

Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€275.22→€222.96

Hold

-10.56%

Downside

Assigned

08/14/26

Alnylam Pharma (ALNY) Gets a Hold from Wells Fargo

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Danielle Brill

Truist Financial

―

Buy

―

Reiterated

09/18/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Dexcom (NASDAQ: DXCM) and Alnylam Pharma (NASDAQ: ALNY)

Joseph Stringer

Needham

€310.93

Buy

24.72%

Upside

Reiterated

09/17/26

Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity

David Lebowitz

BMO Capital

€276.96

Buy

11.10%

Upside

Reiterated

09/17/26

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (NYSE: ELAN) and Alnylam Pharma (NASDAQ: ALNY)

Jeffrey Walch

Bernstein

€327.48

Buy

31.36%

Upside

Reiterated

09/16/26

Analysts' Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)

Michael Ulz

Morgan Stanley

€261.28

Hold

4.81%

Upside

Reiterated

09/11/26

Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained

Faisal Khurshid

Jefferies

€200.32→€226.45

Hold

-9.17%

Downside

Reiterated

09/08/26

Alnylam price target raised to $260 from $230 at JefferiesAlnylam price target raised to $260 from $230 at Jefferies

Patrick Trucchio

H.C. Wainwright

€396.28

Buy

58.96%

Upside

Reiterated

09/02/26

Alnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target

Eliana Merle

Barclays

€391.93

Buy

57.21%

Upside

Reiterated

09/01/26

Barclays Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Cory Kasimov

Evercore ISI

€283.23

Buy

13.61%

Upside

Reiterated

08/31/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Matteis

Stifel Nicolaus

€276.96

Buy

11.10%

Upside

Reiterated

08/31/26

Stifel Nicolaus Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Eric Joseph

Citi

€296.12

Buy

18.78%

Upside

Reiterated

08/31/26

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY)

Tazeen Ahmad

Bank of America Securities

€301.35

Buy

20.88%

Upside

Reiterated

08/31/26

Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility

Edward Tenthoff

Piper Sandler

€425.89

Buy

70.84%

Upside

Reiterated

08/31/26

Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

Whitney Ijem

Canaccord Genuity

€373.64

Buy

49.87%

Upside

Reiterated

08/28/26

Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€275.22→€222.96

Hold

-10.56%

Downside

Assigned

08/14/26

Alnylam Pharma (ALNY) Gets a Hold from Wells Fargo

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AXGNAxoGen

ASNDAscendis Pharma

HROWHarrow Health

IRTCIrhythm Technologies

DNLIDenali Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

3 Months

Keay NakaeChardan Capital

Success Rate

24/39 ratings generated profit

Average Return

+5.47%

Copying Keay Nakae's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +5.47% per trade.

1 Year

Whitney IjemCanaccord Genuity

Success Rate

20/28 ratings generated profit

Average Return

+25.29%

Copying Whitney Ijem's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +25.29% per trade.

2 Years

David LebowitzBMO Capital

Success Rate

32/43 ratings generated profit

Average Return

+41.89%

Copying David Lebowitz's trades and holding each position for 2 Years would result in 74.42% of your transactions generating a profit, with an average return of +41.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DUL Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DUL has received 50 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. DUL average Analyst price target in the past 3 months is 328.62.

Each month's total comprises the sum of three months' worth of ratings.

DUL Financial Forecast

DUL Earnings Forecast

Next quarter’s earnings estimate for DUL is €1.55 with a range of €0.91 to €2.59. The previous quarter’s EPS was €1.05. DUL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.

DUL Sales Forecast

Next quarter’s sales forecast for DUL is €1.24B with a range of €1.10B to €1.30B. The previous quarter’s sales results were €1.12B. DUL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DUL has Performed in-line its overall industry.

DUL Stock Forecast FAQ

What is DE:DUL’s average 12-month price target, according to analysts?

Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 328.62.

What is DE:DUL’s upside potential, based on the analysts’ average price target?

Alnylam Pharmaceuticals has 31.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alnylam Pharmaceuticals a Buy, Sell or Hold?

Alnylam Pharmaceuticals has a consensus rating of Strong Buy, which is based on 19 buy ratings, 3 hold ratings and 0 sell ratings.

What is Alnylam Pharmaceuticals’s share price target?

The average share price target for Alnylam Pharmaceuticals is 328.62. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €479.02 ,and the lowest forecast is €222.96. The average share price target represents 31.82% Increase from the current price of €249.3.

What do analysts say about Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Alnylam Pharmaceuticals?

To buy shares of DE:DUL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Alnylam Pharma (DUL) Stock Forecast & Price Target

DUL Analyst Ratings

DUL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alnylam Pharma

DUL Analyst Recommendation Trends

DUL Financial Forecast

DUL Earnings Forecast

DUL Sales Forecast

DUL Stock Forecast FAQ

Detailed List of Analyst Forecasts